Skip to Main Content

A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma

Conditions

Melanoma, skin

Phase I

What is the purpose of this trial?

This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC.

  • Trial with
    Yale Cancer Center
  • Start Date
    07/30/2020
  • End Date
    12/31/2024

For more information about this study, contact:

Neta Shanwetter Levit

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    08/04/2020
  • Study HIC
    #2000026830